C ytomegalovirus (CMV) is generally acquired early in life, remains latent, and causes no disease manifestations for an undetermined period of time in more than two thirds of the adult population (1) . Once the human host undergoes any process that decreases the immune function, especially T-cell response, the latent CMV may start to replicate again and cause disease manifestations (2) .
CMV is the most common viral opportunistic infection in immunocompromised patients, such as solid organ transplant recipients, hematopoietic stem cell transplant recipients, and patients with solid or hematologic malignancies. The direct CMV manifestations include CMV syndrome (fever, malaise, and cytopenia) and CMV disease (CMV syndrome and/or CMV organ involvement). The indirect CMV manifestations included allograft rejection, atherosclerosis, and further immunosuppression leading to other opportunistic infections, such as bacterial and fungal sepsis (3) .
Active CMV infection may also be associated with the development of a temporary state of immunosuppression induced by prolonged hospitalization or intensive care unit (ICU) stay, severe sepsis, and septic shock, which has been called compensatory anti-inflammatory response syndrome (4) . Animal studies have suggested that animals with bacterial sepsis may be more susceptible to CMV reactivation (5) . Several observational and cohort human studies have been performed and suggested that CMV reactivation or new infection occurs in nonimmunosuppressed ICU patients (6 -18) .
We conducted a systematic review of the literature and meta-analysis to evaluate the prevalence and mortality outcomes associated with active CMV infection in ICU patients who were presumptively immunocompetent before admission.
MATERIALS AND METHODS

Literature Search
A systematic literature search without language restrictions was performed from inception to October 2008 in the following databases: MEDLINE, Embase, and Cochrane Library. Relevant Internet sites such as the U.S. Food and Drug Administration reports and trial results repositories (www.clinicalstudyresults.org and www.clinicaltrialresults.org) were searched. The keywords used were cytomegalovirus, herpes virus, intensive care, critical care, ventilator, sepsis, trauma, critically ill, nonimmunosuppressed, and immunocompetent.
Study Selection
Inclusion Criteria. We included studies that aimed to systematically evaluate the rate of CMV infection in nonimmunosuppressed patients in the ICU setting.
Exclusion Criteria. We excluded studies performed only in immunocompromised patients and/or in non-ICU settings.
Data Extraction
The following variables were collected: authors, publication year, study design, subjects' gender, subjects' mean age, sample size, type of ICU, length of ICU stay, severity-of-illness scores, presence or absence of mechanical ventilation, presence or absence of severe sepsis and septic shock, baseline CMV serostatus, CMV diagnostic method, and survival. Any disagreement was resolved by further review and consensus among the two authors.
Case Definition
Cases were defined by the presence of active CMV infection, where CMV was detected by one or more of the following methods: viral culture, polymerase chain reaction (PCR), or CMV antigen (pp65). The traditional definitions used in immunocompromised patients-CMV syndrome and CMV disease--were not reported in most studies involving nonimmunosuppressed patients. Therefore, these definitions were not evaluated in our study. The term nonimmunosuppressed refers to patients who are neither receiving immunosuppressive medications nor diagnosed with an immunosuppressive disease at ICU admission.
Statistical Analysis
The data were pooled by using the MantelHaenszel fixed-effects model (19) and the DerSimonian and Laird random-effects model (20) . The Cochran Q statistical method was used to assess statistical heterogeneity and the I 2 method to assess the magnitude of variation secondary to heterogeneity (21) . For studies with no event of interest in a treatment group, 1.0 was added to all cells for continuity correction. The software used was Comprehensive Meta-Analysis version 2.2 (Biostat, Englewood, NJ). We followed the QUOROM criteria (22) for the search methodology ( Fig. 1 ) and the MOOSE guidelines (23) for reporting. Both Egger regression and the Begg and Mazumdar methods were used to evaluate publication bias (24) . This study was exempted from institutional review board approval.
RESULTS
Thirteen studies were selected with a total of 1,258 patients (Table 1) . Nine were prospective cohorts (6, 8, 9, 11-14, 16, 17) , and four were retrospective studies (7, 10, 15, 18) . The literature search process is shown in the QUOROM trial diagram (Fig. 1) .
Rate of Active CMV Infection by Previous Exposure and Diagnostic Method
The overall rate of active CMV infection in nonimmunosuppressed ICU patients was 17% (95% CI, 11% to 24%; p Ͻ .0001; Q ϭ 87.07; I 2 ϭ 86%; n ϭ 1258) (Fig. 2a) only the studies that evaluated CMV infections by viral cultures were analyzed, the rate of active CMV infection was 12% (95% CI, 6% to 22%; p Ͻ .0001; Q ϭ 18.10; I 2 ϭ 83%; n ϭ 447) (Fig. 2b) . If only the studies that evaluated CMV infections by PCR/antigen were analyzed, the rate of active CMV infection was 20% (95% CI, 13% to 31%; p Ͻ .0001; Q ϭ 50.74; I 2 ϭ 84%; n ϭ 811) (Fig. 2b) . No differences in the rates of infection were found between PCR and antigen diagnostic methods: PCR only (19% [95% CI, 10% to 32%]; n ϭ 549); pp65 antigen only (17% [8% to 31%]; n ϭ 393).
Considering the different probabilities of CMV reactivation between patients with previous positive or negative immunoglobulin G (IgG) serology for CMV, we performed a separate analysis. For the studies that did not screen, collect, or report the baseline rate of IgG CMV serology (i.e., included both positive-and negative-serology patients) as part of their inclusion criteria, the overall rate of active CMV infection was 7% (95% CI, 3% to 14%; p Ͻ .0001; Q ϭ 21.67; I 2 ϭ 82%; n ϭ 681). For the studies that screened, collected, or reported the baseline rate of positive IgG CMV serology, the overall rate of active CMV infection was 31% (95% CI, 22% to 42%; p Ͻ .0001; Q ϭ 26.40; I 2 ϭ 73%; n ϭ 398) (Fig. 3a) . If only the studies that evaluated CMV infections by viral cultures in patients with positive CMV serology were analyzed, the rate of active CMV infection increased to 22% (95% CI, 7% to 51%; p ϭ .06; Q ϭ 5.66; I 2 ϭ 82%; n ϭ 98). If only the studies that evaluated CMV infections by PCR/antigen in patients with positive CMV serology were analyzed, the rate of active CMV infection increased to 36% (95% CI, 26% to 47%; p ϭ .01; Q ϭ 13.06; I 2 ϭ 62%; n ϭ 300).
Rate of Active CMV Infection by ICU Type and Length of Stay
The rate of infection in medicosurgical ICUs was 8% (95% CI, 3% to 18%; p Ͻ .001; Q ϭ 42.61; I 2 ϭ 88%; n ϭ 683), and the rate for surgical ICUs only was 23% (95% CI, 15% to 34%; p Ͻ .001; Q ϭ 40.38; I 2 ϭ 85%; n ϭ 575). We could not evaluate medical ICUs only because of the lack of studies. For studies that screened for CMV infections before 5 days of ICU stay (early screening) the rate of active CMV infection was 1% (95% CI, 0% to 4%; p ϭ .009; Q ϭ .03; I 2 ϭ 0%; n ϭ 216), whereas for studies with late screening (Ն5 ICU days) the rate was 21% (95% CI, 15% to 29%; p Ͻ .0001; Q ϭ 63.75; I 2 ϭ 84%; n ϭ 1042) (Fig. 3b ). When we analyzed only the studies that evaluated CMV infections by PCR/antigen in patients with positive CMV serology and Ն5 days in ICU, we found that the rate of active CMV infection increased to 36% (95% CI, 26% to 47%; p ϭ .01; Q ϭ 13.06; I 2 ϭ 62%; n ϭ 300) (Fig. 4) .
Rate of Active CMV Infection by Severity of Illness
High disease severity was defined by the following scores: Acute Physiology and Chronic Health Evaluation Ն20, Simplified Acute Physiology Score Ն40, or Sequential Organ Failure Assessment Ն10 based on the severity of illness used in recent severe sepsis trials (25) (26) (27) . The infection rate for high disease severity was 32% (95% CI, 23% to 42%; p ϭ .001; Q ϭ 5.03; I 2 ϭ 40%; n ϭ 225) and for low disease severity was 13% (95% CI, 6% to 27%; p Ͻ .0001; Q ϭ 15.89; I 2 ϭ 87%; n ϭ 361) (Fig. 5a ). For trials that included only patients with severe sepsis and/or septic shock, the rate of active CMV infection was 32% (95% CI, 22% to 45%; p ϭ .008; Q ϭ 0.01; I 2 ϭ 0%; n ϭ 59), whereas the rate for trials with mixed patient population (i.e., with and without severe sepsis) was 15% (95% CI, 9% to 22%; p Ͻ .0001; Q ϭ 70.20; I 2 ϭ 86%; n ϭ 1199) (Fig. 5b ). In trials that included patients with mechanical ventilation only, the rate was 12% (95% CI, 6% to 22%; p Ͻ .0001; Q ϭ 4.98; I 2 ϭ 59%; n ϭ 347), and in trials that had a mixed population (i.e., with and without mechanical ventilation), the rate was 17% (95% CI, 10% to 27%; p Ͻ .0001; Q ϭ 62.55; I 2 ϭ 87%; n ϭ 812).
All-Cause Mortality in Patients With Active CMV Infection
The mortality rate associated with active CMV infection was 1.93 times (95% CI, 1.29 to 2.88; p ϭ .001; Q ϭ 8.38; I 2 ϭ 16.5%; n ϭ 633) as high as that for patients without infection (Fig. 6 ).
Sensitivity Analysis
Both CMV prevalence and all-cause mortality were analyzed by the type of study design. The rate of CMV infection for prospective studies was 17% (95% CI, 10% to 28%; p Ͻ .0001; Q ϭ 49.21; I 2 ϭ 84%; n ϭ 694) and for retrospective studies was 16% (95% CI, 8% to 29%; p Ͻ .0001; Q ϭ 31.38; I 2 ϭ 90%; n ϭ 564). All-cause mortality for prospective studies was 1.58 (95% CI, 0.97 to 2.58; p ϭ .069; Q ϭ 7.05; I 2 ϭ 29%; n ϭ 454) and for retrospective studies was 2.88 (95% Because the use of leukoreduced blood transfusions may decrease the rate of CMV infection, thus potentially confounding our results, we performed a sensitivity analysis on the trials that used only leukoreduced transfusions: the rate of active CMV infection was 19% (95% CI, 8% to 37%; p ϭ .002; Q ϭ 6.03; I 2 ϭ 66%; n ϭ 286). For the trials that did not report the use of leukoreduced transfusions, the infection rate was 16% (95% CI, 10% to 25%; p Ͻ .0001; Q ϭ 77.9; I 2 ϭ 88%; n ϭ 972).
Publication Bias
In the CMV mortality analysis, we detected no publication bias by Egger regression (intercept ϭ -2.27, SE ϭ 1.24, p ϭ 0.13) or Begg and Mazumdar rank correlation (Kendall's ϭ -0.43, p ϭ 0.23). In the CMV prevalence analysis, we detected no publication bias by Egger regression (intercept ϭ -2.92, SE ϭ 1.44, p ϭ .07) or Begg and Mazumdar rank correlation (Kendall's ϭ -0.27, p ϭ 0.24).
DISCUSSION
Cytomegalovirus is a well-known infection in immunocompromised patients, but it has not been part of the routine diagnostic approach for critically ill nonimmunosuppressed patients. Our findings strongly suggest that this virus not only is frequently observed in nonimmunosuppressed patients but it may also be associated with higher ICU mortality rate.
As expected, the rate of active CMV infection was higher when more sensitive diagnostic methods such as PCR/pp65 antigen (20%) were used, compared with viral cultures (12%). However, previous exposure to CMV, based on the positive IgG serology, was an important factor in whether the critically ill patient developed active CMV infection. The rate was 7% for studies that did not report the serology status and 31% for the studies performed only in patients with positive serology. This 7% rate is likely an overestimation because these studies certainly included both positive-and negative-serology patients. The rationale for the higher rate among positive-serology patients is based on the endogenous reactivation, which is a well-described phenomenon with this virus (28) .
When we used PCR/antigen diagnostic methods to evaluate CMV seropositive patients, the rate of active CMV infection increased to 36%, which is similar to the 33% rate found in the recent prospective study by Limaye et al (17) . Should we be surprised that one in three ICU seropositive patients who are not immunocompromised may have active replication of CMV? Probably not. There is substantial evidence from both preclinical and clinical studies to explain the reasons for this high rate. Animal models infected with bacteria have shown CMV reactivation and the development of disease directly related to this virus (29) . ICU patients commonly receive blood transfusions, which could lead to CMV infections through either exogenous transmission or endogenous CMV reactivation by allogeneic stimulation (30) . In addition, close to 300 cases of CMV infections in nonimmunosuppressed patients have been published (31) .
In most studies, the quantitative CMV PCR was not reported. Limaye et al (17) found a direct correlation between the level of viremia and the risk of continued hospitalization or death by 30 days. These data are consistent with prior data show- ing that patients who develop CMV syndrome and/or disease tend to have higher CMV viral loads than patients who do not develop disease (32) . The plasma CMV viral load has been used by clinicians as a marker for CMV disease progression and as a guide for initiating antiviral therapy and monitoring response to treatment. In our systematic review, only the article by Papazian et al (7) clearly demonstrated the occurrence of CMV end-organ disease in nonimmunosuppressed ICU patients by reporting a series of CMV pneumonia diagnosed by histopathologic examination. Interestingly, the rate of CMV infection in studies that screened for Ͻ5 ICU days was 1%, whereas the rate of infection for studies that screened for Ͼ5 ICU days was 21%. This delay in the development of CMV infection can be explained by the biological behavior of this virus, because the time to develop virusinduced disease depends on the complete lytic virus cycle, which requires prolonged time to develop from the latent phase (33) . This association with prolonged ICU could also be related to the high disease severity. We found significantly high rates of CMV infections in patients with severe sepsis/septic shock (32%) and in patients with high severityof-illness scores (32%). Why should patients with severe sepsis and/or sicker patients be more prone to have active CMV infections? There are at least three biological explanations for CMV reactivation in these nonimmunosuppressed patients with high disease severity that could act alone or in combination: 1) patients with severe sepsis can develop a state called immunoparalysis, also called compensatory anti-inflammatory response syndrome (4, 34); 2) bacterial sepsis itself can reactivate latent CMV infection (29) through endotoxin release by bacteria (5) or tumor necrosis factor-␣ production (9, 35) ; and 3) exogenous catecholamine infusion can stimulate CMV activation (36 
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Study name Event rate and 95% CI CMV infection in surgical ICUs (23%), compared with that in medicosurgical ICUs (8%), may also be explained by the preceding reasons, because these patients may have cytokine release directly related to the surgical trauma, endotoxin exposure through bacterial translocation, and viral activation by the frequent use of catecholamine infusion and blood transfusion during surgery. The absence of differences in CMV infection rates between patients with and without mechanical ventilation may be attributable to reporting bias, because the studies with mixed populations clearly included many patients on mechanical ventilation but did not report the CMV rate in this specific subpopulation; alternatively, mechanical ventilation may have no association with CMV reactivation. Distinctly, CMV infection itself may induce immunoparalysis (37) , which could perpetuate the sepsis-induced immunologic effects or predispose patients to secondary infections.
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The all-cause mortality rate associated with active CMV infection was approximately doubled compared with the rate for patients without CMV infection. This is remarkable because the mortality analysis demonstrated very low heterogeneity among different study populations and consistent point estimates across different study designs. Furthermore, this is compatible with the observed higher mortality rate among immunocompromised patients with CMV infection (3). The fact that several studies have shown that the presence of active CMV infection in nonimmunosuppressed ICU patients is associated with higher rate of nosocomial infections (6, 14, 15) , prolonged mechanical ventilation (7, 14 -16) , and prolonged hospital and ICU stay (6, 12, 14 -17) suggests that CMV may be associated with higher mortality rate. Additionally, CMV induces procoagulant and proinflammatory states by its changes in factor X and thrombin generation as well as in von Willebrand factor and plasminogen inhibitor type 1 secretion (38, 39) . These procoagulant and proinflammatory effects could further compromise the survival outcome of critically ill patients. Another possible mortality-associated variable is related to the CMV transmission or reactivation (allogeneic stimulation) by the common practice of blood transfusion in ICUs. Our findings showed that the rate of CMV infections for studies that used leukoreduced blood transfusions was similar to those that did not use it. Either leukoreduction was not that protective or studies underreported their leukoreduced blood transfusion practice. A recent study showed that blood transfusions in critically ill patients were an independent predictor of mortality (40) . We wonder whether this blood transfusion-associated mortality could be related, in part, to the development of active CMV infection. It remains to be evaluated in future trials whether there is a causal relationship, that is, whether CMV is simply a marker of disease severity or an actual cause of mortality in ICU patients.
We recognize several study limitations. We observed substantial heterogeneity among study populations. This was expected because ICUs, in general, admit very diverse critically ill patients. Given that the rate of CMV infection remained consistent among different types of ICU (surgical and medicosurgical) and between different eras (between which ICU standards of care changed), we believe our findings remain robust. Another limitation could be related to the inclusion of retrospective studies, but the sensitivity analysis showed similar results for both retrospective and prospective designs. Last, publication bias was not detected by two methods, but it cannot be completely ruled out.
Our study demonstrates that the factors most likely associated with the development of active CMV infection in the nonimmunosuppressed ICU patient are previous viral exposure (positive CMV serology), prolonged ICU stay (Ն5 days), presence of severe sepsis/septic shock, and high severity of illness.
Given our meta-analysis findings, we propose that an adequately powered, prospective cohort trial (80% power and twosided p value to detect 10% absolute increase in mortality rate with active CMV infection; 300 patients per group) could be designed to evaluate two groups of ICU patients: CMV seropositive with active CMV infection vs. CMV seropositive without active CMV infection. A stratified randomization based on the surgical status would guarantee an even balance of the number of surgical and medical patients. The inclusion criteria would consist of a) positive CMV serology; b) Acute Physiology and Chronic Health Evaluation II score Ն20; and c) ICU stay Ն5 days. CMV PCR would be performed twice weekly (beginning at 5 days) until ICU discharge. If this trial demonstrates that 28-day mortality rate, hospital mortality rate, or both are significantly increased with ac- tive CMV infection despite similar demographics, baseline characteristics, and severity of illnesses, then an interventional trial would be in order. Another possibility is to conduct an interventional trial without performing a prospective cohort study. The advantage of an interventional, randomized, double-blinded trial is that we could potentially demonstrate the usefulness (or not) of an antiviral intervention with respect to survival outcomes. However, we believe that an interventional randomized trial using prophylaxis with anti-CMV drugs is not advisable at this time because the majority of patients would receive no benefit (two thirds of the CMV seropositive patients would not develop active CMV infection), not to mention the potential harm from antiviral drug side effects and drug interactions. We need to better identify which specific ICU patients are at the highest risk for developing active CMV infection in order to better design these future interventional trials. Of note, our meta-analysis demonstrated that patients with severe sepsis are at very high risk for CMV activation. Hence, another way to evaluate this association is to use a similar approach but take advantage of a large severe sepsis trial, which usually enrolls 2,000 patients. These trials are randomized, double-blinded, and usually well balanced with respect to severity of illness. Assuming current epidemiologic data are available, about two thirds of patients in the sepsis trial would have positive serology for CMV. If 32% of these 1,300 seropositive patients develop active CMV infection (as observed in our study), then we would have 400 patients with active CMV infection and 900 controls. This sample size would provide more than adequate statistical power to detect the putative association between mortality rate and active CMV infection.
Our findings strongly suggest that a prospective cohort trial evaluating patients with positive CMV serology, prolonged ICU stay, and high disease severity would yield the best chance to identify the nonimmunosuppressed patients at the highest risk of developing active CMV infection and to determine its effects on mortality rate.
